恶性葡萄胎患者血清Hcy和MMP-2、TIMP-2检测的临床评价  

Clinical Evaluation of Determination the Changes on Serum Hcy and MMP-2,TIMP-2 Levels in Patients with Malignant Hydatidiform Mole

作　　者：陆瑞[1] 李兰亚[1] 徐发林[1] 

机构地区：[1]江苏省沭阳县中医院,223600

出　　处：《放射免疫学杂志》2013年第6期722-723,共2页Journal of Radioimmanology

摘　　要：目的:评估了恶性葡萄胎患者化疗前后血清Hcy和MMP-2、TIMP-2水平的变化及临床意义。方法:应用酶免法和放射免疫分析对32例恶性葡萄胎患者进行了化疗前后血清Hcy和MMP-2、TIMP检测,并与35名正常妇女作比较。结果:恶性葡萄胎患者在化疗前血清Hcy和MMP-2、TIMP-2水平均非常显著地高于正常妇女组(P<0.01),化疗后6个月未复发的29例中其水平明显下降或接近正常,而复发的3例,其水平又回升到化疗前水平(P<0.01)。结论:检测恶性葡萄胎患者血清Hcy和MMP-2、TIMP-2水平的变化可作为患者诊断和疗效观察的参考。Objective To assess the clinical evaluation of serum Hey and MMP-2, TIMP-2 levels both before and after chemotherapy in patients with malignara hydatidiform mole. Methods Semm Hey （with ELISA）, Serum MMP-2, TIMP-2 （with RIA） levels were determined 32 patients with malignant hydatidiform mole and compared with 35 normal parsons served as control. Results Before chemo- therapy serum Hcy and MMP-2,TIMP-2 levels in the patients were significantly higher than those in controls（P 〈0. 01 ） ,6 months after chemotherapy the levels in 29 cases without recurrence remained dropping markedly and approached those in controls. However,in 3 pa- tients with recurrence the levels increased again and approached the former chemotherapy. Conclusion Detection of serum Hcy and MMP-2, IMP-2 levels might be a useful reference for diagnose and therapeutic efficacy in patients with malignant hydalidiform mole.

关 键 词：恶性葡萄胎 同型半胱氨酸 基质金属蛋白酶-2 金属蛋白酶组织抑制因子 

分 类 号：R737.9[医药卫生—肿瘤]